Immunotherapy in the treatment of non-small cell lung cancer (NSCLC) - analysis of epidemiology and cure - review

Kinga Ruszel, Halina Piecewicz-Szczęsna

DOI: http://dx.doi.org/10.12775/JEHS.2020.10.08.024

Abstract


Cancer is the second leading cause of death in Poland. Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Cancer incidence and mortality trends observed in the world and also Poland for many years, have been the resultants of changes associated with exposure to tobacco smoke carcino-gens (active smoking). Until recently, chemotherapy was the main treatment for NSCLC patients. Currently, thanks to the development of numerous research centers around the world, there are several methods of treating patients, which leads to the extension of cancer patients' lives and the improvement of their quality. The immune system plays an important role in controlling and eradicating cancer.  Immune checkpoint inhibitors (ICPs) have shown clear persistent responses and represent the emergence of a new approach to treating patients with NSCLC.  PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T cells that downmodulates effector functions and limits the generation of immune memory. Immunotherapy with monoclonal antibodies targeting with PD-1 and PD-L1 has become standard of care for an increasing number of indications. However, many patients with metastatic non-small cell lung cancer (mNSCLC) experience disease progression after first- and second- line treatment; therefore more treatment options are needed for these patients. Due to the specific characteristics of cancer immunotherapy and the rapid advances in this field, clinical guidelines for the use of these drugs are needed, including patient selection, response monitoring, careful observation of side effects, and biomarker testing.


Keywords


immunotherapy; NSCLC; epidemiology; PD1; PDL-1; oncology

Full Text:

PDF

References


Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, i in. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer. 17 2018;6(1):75.

Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–911.

8703.00.pdf [Internet]. [cytowane 29 lipiec 2020]. Dostępne na: https://www.cancer.org/content/dam/CRC/PDF/Public/8703.00.pdf

Zago G, Muller M, van den Heuvel M, Baas P. New targeted treatments for non-small-cell lung cancer – role of nivolumab. Biologics. 1 sierpień 2016;10:103–17.

Marciniec M, Nowak A, Filip A. Immunomodulatory antibodies in cancer therapy. Nowotwory Journal of Oncology. 2015;65(1):42–7.

Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 24 październik 2011;11(11):805–12.

Didkowska J, Wojciechowska U, Czaderny K, Olasek P, Ciuba A. Nowotwory złośliwe w Polsce w 2017 roku | Cancer in Poland in 2017. :96.

Palenie tytoniu | KRN [Internet]. [cytowane 3 sierpień 2020]. Dostępne na: http://onkologia.org.pl/palenie-tytoniu/

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Elsevier Enhanced Reader [Internet]. [cytowane 29 lipiec 2020]. Dostępne na: https://reader.elsevier.com/reader/sd/pii/S0923753419421534?token=54BB4B7C102E7BF2608B0A197F9F1266D99B95F18280AD822A40F9A24F787B832EF85803BAF1842D6544153ECF601BA1

Antonia SJ, Balmanoukian A, Brahmer J, Ou S-HI, Hellmann MD, Kim S-W, i in. Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. Journal of Thoracic Oncology. 1 październik 2019;14(10):1794–806.

Piórek A, Zaborowska-Szmit M. Atezolizumab — inhibitor PD-L1 w niedrobnokomórkowym raku płuca. Onkologia w Praktyce Klinicznej - Edukacja. 2017;3(5):236–41.

Remon J, Besse B, Soria J-C. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? BMC Med. 13 2017;15(1):55.

Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. kwiecień 2015;14(4):847–56.

Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015;76–83.

Lacouture ME, Wolchok JD, Yosipovitch G, Kähler KC, Busam KJ, Hauschild A. Ipilimumab in patients with cancer and the management of dermatologic adverse events. Journal of the American Academy of Dermatology. 1 lipiec 2014;71(1):161–9.

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, i in. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. J Clin Oncol. 1 kwiecień 2014;32(10):1020–30.

Bernardo SG, Moskalenko M, Pan M, Shah S, Sidhu HK, Sicular S, i in. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Research. luty 2013;23(1):47–54.

Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine Side Effects Induced by Immune Checkpoint Inhibitors. J Clin Endocrinol Metab. 1 kwiecień 2013;98(4):1361–75.


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM




Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

https://pbn.nauka.gov.pl/sedno-webapp/search?search&searchCategory=WORK&filter.inJournal=36616

POL-index 2011 - 2014

https://pbn.nauka.gov.pl/polindex-webapp/browse/journal/journal-32a319c5-a850-4f44-ba70-1418a6087655

BASE 2011 - 2014

https://www.base-search.net/Search/Results?lookfor=Journal+of+Health+Sciences+%28Radom%29&type=all&oaboost=1&ling=1&name=&thes=&refid=dcrespl&newsearch=1

http://elibrary.ru/contents.asp?titleid=37467

http://journal.rsw.edu.pl/index.php/JHS/issue/archive

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska, EuroPub database, NLM Catalog Result - NCBI, BASE, Russian Sciences Index, Arianta.

https://zdb-katalog.de/title.xhtml?idn=1080187162

https://europub.co.uk/journals/22625

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

https://www.ncbi.nlm.nih.gov/nlmcatalog/101679844

Find a library that holds this journal: http://worldcat.org/issn/23918306

 

PBN Poland

https://pbn.nauka.gov.pl/sedno-webapp/journals/49068

POL-index

https://pbn.nauka.gov.pl/polindex-webapp/browse/journal/journal-c39c8169-88d2-45db-9e7f-d948ce9981c4

BASE

https://www.base-search.net/Search/Results?join=AND&bool0[]=AND&lookfor0[]=2391-8306&type0[]=all&page=11&l=pl&oaboost=1&refid=dcpagepl

Redaction, Publisher and Editorial Office

Publisher and Editorial Office
Department of Physical Culture,
Faculty of Earth Sciences and Spatial Management,
Nicolaus Copernicus University in Toruń, Poland
Address: Str. Lwowska 1, 87-100 Toruń, Poland

  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at https://dbh.nsd.uib.no/publiseringskanaler/erihplus/periodical/info?id=485984

Indexed in Index Copernicus Journals Master List.

http://journals.indexcopernicus.com/Journal+of+Education+Health+and+Sport,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

RG Journal Impact: 0.18 *

*This value is calculated using ResearchGate data and is based on average citation counts from work published in this journal. The data used in the calculation may not be exhaustive.

RG Journal impact history

2020Available summer 2021
2018 / 20190.18
20170.07
20160.03

RG Journal impact over time

RG Journal impact
0.180.160.140.120.100.080.060.040.02201620172018
  

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (https://pbn.nauka.gov.pl/journals/36616)

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ) http://elibrary.ru/contents.asp?titleid=37467

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski

(http://www1.bg.us.edu.pl/bazy/czasopisma/czasop_full.asp?id=3595)

Partnerzy platformy czasopism